Your browser is no longer supported. Please, upgrade your browser.
Aziyo Biologics, Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own9.02% Shs Outstand10.23M Perf Week15.77%
Market Cap105.70M Forward P/E- EPS next Y-1.26 Insider Trans1.00% Shs Float3.32M Perf Month-15.57%
Income-25.30M PEG- EPS next Q-0.54 Inst Own90.40% Short Float4.75% Perf Quarter-30.58%
Sales42.70M P/S2.48 EPS this Y-112.20% Inst Trans0.01% Short Ratio8.37 Perf Half Y2.23%
Book/sh2.04 P/B5.40 EPS next Y36.30% ROA- Target Price20.00 Perf Year-
Cash/sh4.08 P/C2.70 EPS next 5Y- ROE- 52W Range9.31 - 18.20 Perf YTD-19.22%
Dividend- P/FCF- EPS past 5Y- ROI-31.00% 52W High-39.51% Beta-
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin48.20% 52W Low18.26% ATR0.80
Employees163 Current Ratio2.20 Sales Q/Q12.60% Oper. Margin-30.00% RSI (14)42.49 Volatility10.60% 6.55%
OptionableNo Debt/Eq1.47 EPS Q/Q-72.60% Profit Margin-53.30% Rel Volume0.70 Prev Close11.03
ShortableYes LT Debt/Eq0.86 EarningsMay 04 AMC Payout- Avg Volume18.83K Price11.01
Recom2.00 SMA20-5.60% SMA50-16.43% SMA200-18.13% Volume13,191 Change-0.18%
Nov-02-20Initiated Truist Buy $20
Nov-02-20Initiated Piper Sandler Overweight $20
Nov-02-20Initiated Cowen Outperform $20
Nov-02-20Initiated Cantor Fitzgerald Overweight $20
May-04-21 04:05PM  
Apr-28-21 04:05PM  
Apr-26-21 04:05PM  
Apr-20-21 04:05PM  
Mar-01-21 04:05PM  
Feb-18-21 04:05PM  
Feb-17-21 04:05PM  
Feb-15-21 12:00PM  
Feb-11-21 04:05PM  
Jan-28-21 04:05PM  
Jan-12-21 09:00AM  
Jan-10-21 11:58PM  
Nov-19-20 04:05PM  
Nov-17-20 04:05PM  
Nov-16-20 04:05PM  
Nov-12-20 04:05PM  
Nov-05-20 04:05PM  
Oct-08-20 03:35PM  
Oct-07-20 08:52PM  
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LLOYD RONALD K.PRESIDENT AND CEOMay 07Buy11.758,565100,64323,151May 11 04:40 PM
HighCape Capital, L.P.10% OwnerOct 13Buy17.00441,1767,499,9924,508,831Oct 13 09:57 PM